Research use only. Nothing on this page is medical advice.
Ipamorelin is not shown to cause fat loss. The only direct fat data, from mice, show more fat. No published human trial has measured fat loss with it.
- Mice: ipamorelin raised relative body fat and food intake (1).
- People: the largest trial, 117 patients after bowel surgery, tested gut recovery and found no difference from placebo (2).
- Similar drugs that also trigger growth hormone release, MK-677 and capromorelin, raised lean mass with no fat loss shown (3, 4).
- What does reduce fat in trials: tesamorelin for HIV belly fat, and semaglutide and tirzepatide for weight (5, 6, 7).
Jump to the evidence table, why it may add fat, what works instead, risks or the FAQ.
Does ipamorelin burn fat? What the studies show
How to read the table. Fat rose, None: no fat loss shown. No difference, Hormone only, No fat change, Lean mass only: studies that did not show fat loss. Fat loss: fat fell in trials.
| Study | What it found | Main limit |
|---|---|---|
| Mouse study, ipamorelin | Fat roseIpamorelin raised fat pad weight and relative body fat on a DEXA body scan. It also raised leptin (a fullness hormone) and food intake in mice with normal growth hormone (GH). GH itself lowered fat in GH-deficient mice (1) | Mice, so human relevance is unknown |
| Human fat-loss trials of ipamorelin | NoneA 2026 review of GH-axis peptides lists no body-composition trials for this secretagogue group (8) | Nothing exists to build a timeline on |
| Largest human trial: 117 patients after bowel surgery | No differenceIpamorelin given through a vein (IV) for up to 7 days. Median time to a first tolerated meal was 25.3 hours versus 32.6 on placebo (p = 0.15). Adverse events were 87.5% versus 94.8% (2) | It tested gut recovery, not fat |
| Phase 1 study, healthy adults | Hormone onlyA clear GH response that peaked about 40 to 60 minutes after a dose, with no significant effect on other pituitary or adrenal hormones (8) | A rising hormone is not falling fat |
| MK-677 (oral secretagogue): 24 obese men, 8 weeks | No fat changeFat-free mass rose. Total and visceral (deep belly) fat did not change significantly. Glucose tolerance worsened (3) | Different drug, taken by mouth |
| Capromorelin (oral secretagogue): 395 adults aged 65 to 84 | Lean mass onlyAt 6 months lean mass rose 1.4 kg versus 0.3 kg on placebo, and body weight rose 1.4 kg. Fasting glucose, HbA1c (3-month blood sugar) and insulin resistance rose slightly (4) | Different drug, taken by mouth |
| Tesamorelin (works through a different receptor): HIV belly fat | Fat lossVisceral fat fell and the drop held at about 18% over 52 weeks (5). In a 6-month trial, visceral fat area fell by 34 cm2 versus a rise of 8 cm2 on placebo (9) | Only in HIV patients with excess belly fat, and the loss did not last after treatment stopped (5) |
Why would ipamorelin add fat?
Ipamorelin switches on the ghrelin receptor, the one the hunger hormone ghrelin uses (8).
- The mouse study found fat gain that did not depend on growth hormone, possibly because the mice ate more. Both ipamorelin and a related secretagogue raised food intake (1).
- Ipamorelin is selective. It did not raise the stress hormones ACTH and cortisol, even at doses over 200 times the GH-releasing dose in swine (10). That clean profile is separate from any effect on fat.
- Reviews list appetite changes among the reported adverse effects of this peptide group (8).
What has trial data for fat loss?
- Semaglutide: average weight loss of 14.9% at week 68, against 2.4% on placebo, alongside a lifestyle program (6).
- Tirzepatide: 15.0% to 20.9% at week 72 depending on dose group, against 3.1% on placebo (7).
- Tesamorelin: lower visceral (deep belly) fat in HIV patients with excess belly fat, which returns after treatment stops (5).
Semaglutide and tirzepatide are FDA-approved prescription drugs. See peptides for weight loss graded by human evidence and fat loss peptides.
What are the risks of ipamorelin?
- Not approved. No regulator has approved it for any body-shaping or performance use (8), and long-term safety data do not exist (11).
- FDA concerns. FDA lists ipamorelin as a compounding risk. It flags immunogenicity, an immune reaction to clumped or impure peptide, and cites serious adverse events including death in a study that gave it by IV for gut motility (12).
- Blood sugar. Related secretagogues worsened glucose handling (3, 4), and reviews list dysglycemia (blood sugar problems) among reported effects (8).
- Cell growth. Reviews call the concern that it could drive abnormal cell growth biologically plausible but unproven (8).
- Stacking. The CJC-1295 plus ipamorelin combination rests on anecdote, with limited controlled evidence for added benefit in healthy people (8).
- Sport. WADA bans ipamorelin under its growth hormone secretagogue class (13).
What should you do instead?
- Talk to a doctor or endocrinologist about your weight. Approved options have trial data.
- Tell your doctor about any peptide you use.
- If you buy ipamorelin for research anyway, match the lot number to its lab report with our COA guide, and compare sellers in ipamorelin vs sermorelin and best peptide vendors.
More reading: side effects of ipamorelin, CJC-1295 with ipamorelin, ipamorelin for women, peptides for men, GHRH peptides and AOD-9604.
Ipamorelin for fat loss FAQ
Does ipamorelin burn fat?
Not shown. The only direct fat data are from mice, where ipamorelin raised body fat and food intake. No published human trial has measured fat loss with it.
Can ipamorelin help you lose weight?
No trial shows it. In the largest human trial, 117 patients after bowel surgery, ipamorelin did not beat placebo for gut recovery, and weight was not the goal. Approved options with weight-loss trials are semaglutide and tirzepatide.
How long does ipamorelin take to work for fat loss?
There is no human timeline, because no trial measured fat loss. Growth hormone peaks about 40 to 60 minutes after a dose in healthy adults, but a hormone peak is not fat loss.
Does ipamorelin increase appetite?
In mice, yes. Ipamorelin and a related secretagogue raised food intake and leptin. Reviews list appetite changes among reported adverse effects for this peptide group.
Is CJC-1295 with ipamorelin better for fat loss?
No controlled evidence shows it. A 2026 review calls the combination anecdotal, with limited controlled evidence for added body composition benefits in healthy people.
What peptide is best for fat loss?
Tesamorelin has trial data for visceral fat in HIV patients with excess belly fat. Semaglutide and tirzepatide have weight-loss trials of 68 and 72 weeks. Ipamorelin has none.
Is ipamorelin approved or safe?
It is not approved for any use, long-term safety data do not exist, and FDA lists it as a compounding risk.
Is ipamorelin banned in sport?
Yes. WADA bans ipamorelin under its growth hormone secretagogue class.
Sources
Show references (13)Hide references
- Lall S, et al. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun 2001. Source
- Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014. Source
- Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 1998. Source
- White HK, et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab 2009. Source
- Falutz J, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 2008. Source
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021. Source
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022. Source
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol 2026. Source
- Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA 2014. Source
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. Source
- Mavrych V, et al. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging 2026. Source
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (category 2). Page current as of 22 April 2026. Source
- WADA. The 2026 Prohibited List. Source